Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-1798
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents

Oncotarget
Oncology
2018English

Identifying Adverse Drug Events in Older Community-Dwelling Patients

Annals of Family Medicine
Family Practice
2019English

A Large-Scale Survey of Adverse Events Experienced in Yoga Classes

BioPsychoSocial Medicine
PsychiatrySocial PsychologyMental HealthPsychologyBiological Psychiatry
2015English

Advances in the Study of Molecularly Targeted Agents to Treat Hepatocellular Carcinoma

Drug discoveries & therapeutics
MedicineToxicologyPharmaceuticsPharmacology
2014English

In Vitro Study of the Anti-Cancer Effects of Artemisone Alone or in Combination With Other Chemotherapeutic Agents

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2010English

Tackling Burkitt Lymphoma in Older Patients: Novel Strategies and the Promise of Targeted Agents

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

Efficacy of Peloidotherapy Alone or in Combination With Hydrotherapy in Osteoartritis

Boletin Sociedad Española Hidrologia Medica
2018English

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer
Cancer ResearchOncology
2009English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy